Reviews

Understanding Bereavement: What Every Oncology Practitioner Should Know

Death and dying are ever-present in the practice of oncology. Oncology clinic staff regularly encounter terminally ill patients and grieving family members and, therefore, are well positioned to identify and intervene on behalf of those at risk for extreme psychological distress.



 

The Journal of Supportive Oncology

Volume 9, Issue 5, September-October 2011, Pages 172-180

doi:10.1016/j.suponc.2011.04.007
Permissions & Reprints


Review

Understanding Bereavement: What Every Oncology Practitioner Should Know
Elizabeth Kacel BA, Xin Gao BS, Holly G. Prigerson PhD
Received 4 January 2011; Accepted 29 March 2011. Available online 24 September 2011.

Abstract

Death and dying are ever-present in the practice of oncology. Oncology clinic staff regularly encounter terminally ill patients and grieving family members and, therefore, are well positioned to identify and intervene on behalf of those at risk for extreme psychological distress. It is important for oncology providers to understand grief, the factors that heighten the risk for maladjustment to the loss, and how best to ease the emotional pain and suffering of bereaved family members. This article highlights models of grief that examine early relationships, relationships at the time of the loss, cognitive processes, and cultural practices. We also discuss special circumstances of grief such as the loss of a child or parent and grief in young adults. Risk factors for severe grief reactions, specifically prolonged grief disorder, are examined, as are the efficacy of various interventions, including staff support, psychodynamic therapy, cognitive-behavioral therapy, interpersonal therapy, group therapy, and Internet interventions. Overall, the literature on treatment for grief has demonstrated mixed results, but some therapies have shown promise in treating particularly distressed families and individuals. We discuss the clinical significance of grief and the importance of recognizing the unique factors which contribute to individuals' abilities to cope with loss.

*For a PDF of the full article and accompanying viewpoints by Noreen Carrington and Charles F. von Gunten and Judith Lacey, click on the links to the left of this introduction.

Recommended Reading

New Nomograms Predict Lymphedema After Axillary Lymph Node Dissection
MDedge Hematology and Oncology
FDA Panel: Update Bisphosphonate Labeling
MDedge Hematology and Oncology
Venlafaxine, Clonidine Top Placebo for Breast Cancer Hot Flashes
MDedge Hematology and Oncology
Arrhythmia Risk Leads to Ondansetron Label Changes
MDedge Hematology and Oncology
Denosumab Approved for Bone Loss From Hormone Ablation Therapy
MDedge Hematology and Oncology
Commentary: Depression Stymies Care in Latina Breast Cancer Survivors
MDedge Hematology and Oncology
Taxane-Induced Neuropathy Gives No Clue to Breast Cancer Outcomes
MDedge Hematology and Oncology
Ibandronate Relieves Metastatic Prostate Cancer Bone Pain
MDedge Hematology and Oncology
ASCO Updates Guidelines on Antiemetics in Oncology
MDedge Hematology and Oncology
Quality care is a team effort
MDedge Hematology and Oncology